Is Bristol-Myers Squibb ([[BMY]]) going to buy Celgene ([[CELG]]) or not? Most such deals go through, but the exceptions are big ones (such as Pfizer's ([[PFE]]) bid for AstraZeneca ([[AZN]])). The uncertainty has come in because of yesterday's announcement from Wellington Management Company, the largest institutional holder of BMY (8% of common shares), that they oppose the deal. You can tell that the markets took this seriously - Celgene stock went down 8% yesterday, while Bristol-Myers Squibb stock went up.
Why stand in the way? Wellington says that they don't like the idea of the